New Antimitotic Agents with Activity in Multi-Drug-Resistant Cell Lines and in Vivo Efficacy in Murine Tumor Models
β Scribed by Szczepankiewicz, Bruce G.; Liu, Gang; Jae, Hwan-Soo; Tasker, Andrew S.; Gunawardana, Indrani W.; von Geldern, Thomas W.; Gwaltney, Stephen L.; Wu-Wong, J. Ruth; Gehrke, Laura; Chiou, William J.; Credo, R. Bruce; Alder, Jeffery D.; Nukkala, Michael A.; Zielinski, Nicolette A.; Jarvis, Ken; Mollison, Karl W.; Frost, David J.; Bauch, Joy L.; Hui, Yu Hua; Claiborne, Akiyo K.; Li, Qun; Rosenberg, Saul H.
- Book ID
- 118069557
- Publisher
- American Chemical Society
- Year
- 2001
- Tongue
- English
- Weight
- 224 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0022-2623
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The in vivo anti-tumor activity of 2 recombinant cytokines, interleukin-2 (rlL-2) and human hybrid interferon alpha (rHulFN-aA/D), were tested using the murine reticulum cell sarcoma M5076. Experimental hepatic metastases, following i.v. injection of tumor cells, and tumor growth and spontaneous met
Interferon-gamma (IFN-y) treatment or in vivo passage of the murine YAC-I lymphoma resulted in reduced sensitivity to in vitro lysis by syngeneic murine spleen cells cultured in rll-2 (LAK-cells). IFN-y treatment also rendered the murine B16 melanoma less sensitive to lysis by syngeneic LAK cells, w